Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
Avenue Therapeutics has successfully completed a $2 million public offering of common stock, with Aegis Capital Corp. acting as the sole bookrunner.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avenue Therapeutics has successfully completed a $2 million public offering of common stock, with Aegis Capital Corp. acting as the sole bookrunner. The funds raised will support the company’s ongoing development of IV tramadol, an alternative aimed at reducing opioid use for patients with acute pain in the U.S. Avenue Therapeutics is headquartered in New York City and is focused on innovative solutions for pain management.
Positive
- Raised $2 million to support ongoing development of IV tramadol.
- Potential to reduce opioid use, addressing a critical healthcare need.
Negative
- Dilution risk for existing shareholders due to the public offering.
Details
News Market Reaction – ATXI
The recorded move for ATXI in the trading session of this news was -10.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a
About Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City.
For more information, visit www.avenuetx.com
About Aegis Capital Corporation
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.
For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.
Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC. Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.
SOURCE: Aegis Capital Corp.
View source version on accesswire.com:
https://www.accesswire.com/677906/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-2-Million-Public-Offering-of-Common-Stock-for-Avenue-Therapeutics-NASDAQ-ATXI
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.